SBP Group Eyes Innovation as It Shifts Beyond Generics

SBP Group's CEO Eric Tse has unveiled plans to pivot from their traditional generics-focused model to a more innovative drug development strategy, reflecting a broader trend in China's healthcare sector. Speaking at the World Economic Forum's Annual Meeting of the New Champions, Tse emphasized the group's ambition to become a player in cutting-edge pharmaceutical research. This strategic shift is significant as it positions SBP Group to meet evolving healthcare demands and potentially secure a larger market share in advanced therapies.